Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00136084Phase 3Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Aug 2002
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Minimal Residual Disease at Day 22. Started Aug 2002; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT00136084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136084.